BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36809797)

  • 1. TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently.
    Kim HS; Kim BR; Dao TTP; Kim JM; Kim YJ; Son H; Jo S; Kim D; Kim J; Suh YJ; Kim HJ; Cho BS; Park S
    Blood Adv; 2023 Jul; 7(13):3155-3168. PubMed ID: 36809797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia.
    Gabellier L; De Toledo M; Chakraborty M; Akl D; Hallal R; Aqrouq M; Buonocore G; Recasens-Zorzo C; Cartron G; Delort A; Piechaczyk M; Tempé D; Bossis G
    Haematologica; 2024 Jan; 109(1):98-114. PubMed ID: 37608777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation.
    Baakhlagh S; Kashani B; Zandi Z; Bashash D; Moradkhani M; Nasrollahzadeh A; Yaghmaei M; Mousavi SA; Ghaffari SH
    Int Immunopharmacol; 2021 Jan; 90():107202. PubMed ID: 33278749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
    Barghout SH; Patel PS; Wang X; Xu GW; Kavanagh S; Halgas O; Zarabi SF; Gronda M; Hurren R; Jeyaraju DV; MacLean N; Brennan S; Hyer ML; Berger A; Traore T; Milhollen M; Smith AC; Minden MD; Pai EF; Hakem R; Schimmer AD
    Leukemia; 2019 Jan; 33(1):37-51. PubMed ID: 29884901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
    Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
    Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Tumor and Immune Enhancing Activities of Rice Bran Gramisterol on Acute Myelogenous Leukemia.
    Somintara S; Leardkamolkarn V; Suttiarporn P; Mahatheeranont S
    PLoS One; 2016; 11(1):e0146869. PubMed ID: 26752299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
    Lightcap ES; Yu P; Grossman S; Song K; Khattar M; Xega K; He X; Gavin JM; Imaichi H; Garnsey JJ; Koenig E; Zhang H; Lu Z; Shah P; Fu Y; Milhollen MA; Hatton BA; Riceberg J; Shinde V; Li C; Minissale J; Yang X; England D; Klinghoffer RA; Langston S; Galvin K; Shapiro G; Pulukuri SM; Fuchs SY; Huszar D
    Sci Transl Med; 2021 Sep; 13(611):eaba7791. PubMed ID: 34524860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the SUMO Pathway Primes All-
    Baik H; Boulanger M; Hosseini M; Kowalczyk J; Zaghdoudi S; Salem T; Sarry JE; Hicheri Y; Cartron G; Piechaczyk M; Bossis G
    Cancer Res; 2018 May; 78(10):2601-2613. PubMed ID: 29487199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Clinical Activity of Amino-Alcohol Dimeric Naphthoquinones as Potential Therapeutics for Acute Myeloid Leukemia.
    Ferraris D; Lapidus R; Truong P; Bollino D; Carter-Cooper B; Lee M; Chang E; LaRossa-Garcia M; Dash S; Gartenhaus R; Choi EY; Kipe O; Lam V; Mason K; Palmer R; Williams E; Ambulos N; Kamangar F; Zhang Y; Kapadia B; Jing Y; Emadi A
    Anticancer Agents Med Chem; 2022; 22(2):239-253. PubMed ID: 34080968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nobiletin Down-Regulates c-KIT Gene Expression and Exerts Antileukemic Effects on Human Acute Myeloid Leukemia Cells.
    Chen PY; Chen YT; Gao WY; Wu MJ; Yen JH
    J Agric Food Chem; 2018 Dec; 66(51):13423-13434. PubMed ID: 30507186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
    Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
    Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
    Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
    Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
    Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
    Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.